{"keywords":["Acquired resistance","Chemotherapy","EGFR-TKI","NSCLC","Pemetrexed","Rechallenge"],"meshTags":["Adenocarcinoma","Antineoplastic Combined Chemotherapy Protocols","DNA Mutational Analysis","Drug Resistance, Neoplasm","Erlotinib Hydrochloride","Glutamates","Guanine","Humans","Lung Neoplasms","Maintenance Chemotherapy","Male","Middle Aged","Mutation, Missense","Neoplasm Recurrence, Local","Pemetrexed","Quinazolines","Radiography","Receptor, Epidermal Growth Factor","Treatment Outcome"],"meshMinor":["Adenocarcinoma","Antineoplastic Combined Chemotherapy Protocols","DNA Mutational Analysis","Drug Resistance, Neoplasm","Erlotinib Hydrochloride","Glutamates","Guanine","Humans","Lung Neoplasms","Maintenance Chemotherapy","Male","Middle Aged","Mutation, Missense","Neoplasm Recurrence, Local","Pemetrexed","Quinazolines","Radiography","Receptor, Epidermal Growth Factor","Treatment Outcome"],"genes":["EGFR-TKI","epidermal growth factor receptor","EGFR","EGFR","EGFR","L858R"],"organisms":["9606","9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. We report a case here that an advanced lung adenocarcinoma with L858R mutation responded well to pemetrexed rechallenge after acquired resistance of erlotinib.","title":"Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.","pubmedId":"24636847"}